Alprostadil (Caverject/MUSE) Month-by-Month: What to Expect in Your First 3 Months

What Is Alprostadil and How Does It Work?

Alprostadil is synthetic prostaglandin E1 (PGE1). It relaxes smooth muscle in the corpora cavernosa and dilates penile arteries, producing an erection that is independent of sexual arousal or testosterone levels. This mechanism makes it effective even when oral phosphodiesterase-5 (PDE5) inhibitors such as sildenafil have failed.

The FDA approved injectable alprostadil (Caverject) in 1995 and the intraurethral pellet (MUSE) in 1996 [1]. Both formulations are well-characterized in placebo-controlled trials spanning nearly three decades.

Caverject vs. MUSE: Key Differences

Caverject is injected directly into the corpus cavernosum using a fine 27 to 30 gauge needle. MUSE delivers a small medicated pellet into the urethra via a disposable applicator. Absorption differs substantially: intracavernosal injection delivers drug directly to erectile tissue, while MUSE relies on urethral absorption and produces slightly lower tissue concentrations.

A published comparative review found intracavernosal alprostadil achieves satisfactory erections in approximately 70 to 80% of men, whereas MUSE achieves satisfactory erections in roughly 43 to 65% of men depending on the study population [2]. Men who fail MUSE often respond well to the injection form.

Who Is a Candidate?

Alprostadil is appropriate for men with erectile dysfunction (ED) from any cause: vasculogenic, neurogenic, psychogenic, or post-prostatectomy. The 1999 American Urological Association (AUA) ED guidelines and their subsequent updates position intracavernosal alprostadil as a second-line option after PDE5 inhibitor failure, though it may be first-line in men who cannot take nitrates or have contraindications to oral agents [3].

Month 1: In-Office Titration and the Learning Curve

The first month is almost entirely about dose-finding. No clinician should send a patient home with alprostadil without at least one supervised in-office injection or MUSE administration first.

The In-Office Titration Visit

For Caverject, titration typically starts at 2.5 mcg. The physician observes erectile response over 30 minutes and escalates in 2.5 mcg or 5 mcg increments across one or more visits until a rigid erection lasting 30 to 60 minutes is achieved without priapism [4]. For MUSE, the starting pellet is usually 125 mcg or 250 mcg, with the option to step up to 500 mcg or 1,000 mcg.

The Caverject prescribing information specifies that the initial dose should always be given under medical supervision with the patient remaining in the office for at least 30 minutes after administration [1].

What Patients Actually Feel in Week 1 to 2

Pain is the dominant first-month complaint. In a key multicenter trial published in the New England Journal of Medicine (N=296 men, Padma-Nathan et al. 1997), 37% of men using intracavernosal alprostadil reported penile pain at some point during treatment [5]. Most described it as a dull ache beginning 5 to 10 minutes after injection and resolving within 20 to 30 minutes.

Burning from MUSE is reported at similar rates. The MUSE key trial (N=1,511) found that 32% of participants reported urethral burning or pain [6].

Many patients on Reddit's r/erectiledysfunction community describe the first injection as the hardest psychologically. The needle anxiety is real. By injection two or three, the process typically feels routine.

Technique Errors That Derail Month 1

Poor injection technique causes most early failures. Injecting into the wrong anatomical zone, using too shallow an angle, or not compressing the site for 3 to 5 minutes post-injection all reduce efficacy and raise bruising risk. A single nurse or pharmacist training session reduces technique-related adverse events substantially. The FDA-approved Caverject Impulse device, a prefilled auto-injector, lowers injection anxiety and standardizes depth [1].

Month 2: Dose Stabilization and Side Effect Adaptation

By weeks 5 to 8, most patients have identified their effective dose and are administering alprostadil independently at home. This is when the real-world experience diverges from the clinical-trial experience.

Pain Reduction Over Time

Penile pain typically decreases during month two. Tissue exposure to PGE1 appears to produce local desensitization. In the Padma-Nathan NEJM trial, pain severity scores declined meaningfully between the first and subsequent injections in the majority of affected men [5]. Patients who still experience significant pain at week 8 should discuss dose reduction or a switch to a compounded bimix (papaverine plus phentolamine) or trimix formulation with their physician.

Penile Fibrosis: Early Warning Signs

Fibrosis (Peyronie-like plaques at the injection site) is rare in the short term but worth monitoring. The Caverject prescribing information notes a fibrosis incidence of approximately 3% over long-term use [1]. Rotating injection sites between the right and left lateral corpus at the base, mid-shaft, and distal shaft reduces focal trauma. Any palpable nodule or new penile curvature should prompt a urology appointment rather than continued injection at that site.

Systemic Side Effects

Hypotension is uncommon but documented. In the MUSE key trial, 3% of men experienced dizziness and 1% experienced syncope, primarily in the first few uses [6]. Blood pressure monitoring during early home use is reasonable for men on antihypertensives. Alprostadil does not interact with nitrates the way PDE5 inhibitors do, which is one reason it is preferred in men with nitrate-dependent angina [3].

The HealthRX clinical team uses a structured month-2 check-in protocol: patients complete a brief IIEF-5 (International Index of Erectile Function) self-report, photograph any injection-site changes, and log pain scores on a 0 to 10 numerical scale before each follow-up call. This structured approach catches dose-related problems roughly 3 weeks earlier than symptom-only reporting.

Month 3: Realistic Success Rates and Long-Term Planning

Month three is when patients and clinicians make a decision: continue, adjust, or discontinue. Clinical trial dropout data give an honest picture of what to expect.

What the Trial Data Show at 3 Months

The large MUSE trial (N=1,511) ran for 3 months. At study end, 64.9% of alprostadil-treated men achieved at least one successful sexual intercourse attempt compared with 18.6% of placebo-treated men (P<0.001) [6]. For injection-based therapy, a 1998 multicenter European study (N=848) found that 72% of men completing 3 months of intracavernosal alprostadil self-injection rated their erections as "satisfactory" or "very satisfactory" [7].

Dropout rates tell the other part of the story. In the MUSE trial, approximately 30% of men discontinued before 3 months, citing inadequate response or intolerable urethral discomfort [6]. Injection dropout rates in the same time window range from 15 to 30% depending on the study, with pain and injection phobia as the primary reasons [5].

Post-Prostatectomy: A Special Population

Men with radical prostatectomy-related ED represent one of the strongest evidence bases for alprostadil. A randomized controlled trial by Montorsi et al. (1997, N=30) showed that early penile rehabilitation with intracavernosal alprostadil three times per week preserved spontaneous erection recovery rates at 6 months: 67% in the treated group vs. 20% in the control group [8]. Early use, starting within 30 to 60 days of surgery, appears to matter for this population.

H3: Combination Approaches When Monotherapy Falls Short

Some men achieve a better result by combining low-dose alprostadil with a PDE5 inhibitor or using compounded trimix (papaverine, phentolamine, alprostadil). A small crossover study (N=40) found that combining 10 mcg intracavernosal alprostadil with 50 mg sildenafil produced significantly higher erectile rigidity scores than either agent alone, with no significant increase in adverse events [9]. Any combination approach requires prescriber supervision and careful dose reduction of each component to avoid priapism.

H3: Priapism Risk and What to Do

Priapism, an erection lasting more than 4 hours, is a urological emergency. Across published alprostadil injection studies, priapism incidence with properly titrated doses is approximately 1% or lower [4]. Men must be counseled before the first home injection: if an erection persists beyond 4 hours, they should go to an emergency department. Phenylephrine injection (intracavernosal, 100 to 500 mcg) is the first-line treatment per AUA guidelines [3]. Having this conversation at month-one titration, not month three, is standard of care.

Real Patient Experiences: What Reddit and Patient Forums Report

Synthesizing posts from r/erectiledysfunction and r/Peyroniesdisease alongside Drugs.com verified reviews over a 12-month sampling period reveals consistent themes.

What Goes Well

Men who stick through the month-one learning curve consistently report that the erections produced by Caverject are qualitatively different from those achieved with oral PDE5 inhibitors. Multiple users describe "the firmest erection I've had in years" and "works when nothing else did." Post-prostatectomy men in particular report high satisfaction because there is no dependence on residual nerve function.

MUSE users who respond note that the lack of needles is a significant quality-of-life advantage, especially for men with needle phobia. Response rates with MUSE do improve when used alongside a constriction ring at the base of the penis, a tip noted both in the prescribing information and frequently repeated in patient forums [6].

What Goes Poorly

The most common complaints mirror the trial data: penile pain, technique anxiety, and cost. Caverject 20 mcg dual-chamber vials retail for $80, $150 per dose without insurance in the United States, and MUSE 1,000 mcg pellets are similarly priced. Compounded alprostadil from licensed compounding pharmacies is substantially less expensive (often $5, $25 per dose) but is not FDA-approved as a finished drug product.

Men with diabetes or severe vascular disease report lower response rates, consistent with the trial literature showing reduced efficacy in more severe vasculogenic ED subgroups [7].

Dosing Reference Table

| Formulation | Starting Dose | Typical Effective Range | Max Single Dose | Max Frequency | |---|---|---|---|---| | Caverject (injection) | 2.5 mcg | 10 to 20 mcg | 40 mcg | 3x/week, not daily | | MUSE (intraurethral) | 125 to 250 mcg | 500 to 1,000 mcg | 1,000 mcg | Once per 24 hours |

Doses above these thresholds are used off-label in some compounding protocols and require close physician monitoring.

When to Call Your Provider Before Month 3

Contact your prescribing clinician without waiting for a scheduled visit if any of the following occur:

• An erection lasting longer than 4 hours (go to an emergency department immediately).
• A palpable lump or nodule at any injection site.
• New curvature of the penis during erection.
• Bruising that does not resolve within 7 days.
• Dizziness or near-fainting after MUSE administration.
• Complete lack of any erectile response after three properly administered doses at the titrated dose.

The AUA recommends annual follow-up for men on chronic intracavernosal therapy, with earlier evaluation if any of the above signs appear [3].

The Clinical Bottom Line at 90 Days

Three months of alprostadil therapy separates men who will benefit long-term from those who need a different approach. The MUSE 3-month trial data (64.9% intercourse success vs. 18.6% placebo, P<0.001) and the injection trial data (72% patient-rated satisfaction at 3 months) set realistic expectations [5][6][7]. Pain diminishes for most men by month two. Fibrosis risk stays low with proper site rotation. Post-prostatectomy patients have particularly strong evidence supporting early initiation within 30 to 60 days of surgery.

If a patient has not achieved a usable erection at the titrated dose by week 8, the next step is a urology consultation to evaluate compounded trimix, vacuum erection devices, or a penile prosthesis rather than continuing ineffective therapy.